Connect with us

Entrepreneur

Femtech firm launches genetic test for perimenopause

Published

on

A new commercially available genetic test for perimenopausal women has been launched by femtech firm Willbe. 

The FemGene test is aimed at decoding “how women uniquely experience perimenopause and respond to bioidentical hormone therapy (BHRT)”.

Perimenopause, affecting over 1 billion women globally, remains one of the most underserved areas of healthcare, WIllbe says.

Standard approaches , the firm says, often rely on years of trial and error, leaving women and their doctors frustrated, unsupported, and at risk of preventable age-related conditions.

Willbe aims to predict how a woman’s body will metabolise and respond to declining hormones, long before symptoms take hold.

Its approach classifies women into distinct hormonal archetypes “rooted in genetics that guide treatment pathways with accuracy and confidence”.

This, it says, “enables faster relief, longer adherence to BHRT, and ultimately supports healthier, longer lives for women”.

The company was founded by biomedical scientist and entrepreneur Yulia Mintchin

She says: “Perimenopause is not just declining hormones — it’s an epigenetic reprogramming event.

“The body says: the way I used to run no longer works. Whether a woman thrives or struggles is written in her genes.

“As hormones decline, gene expression shifts — driving how she ages, repairs, and restores. That’s why women on the same HRT dose can have completely different outcomes.

“By decoding each woman’s genetic blueprint, we can predict her hormonal journey and deliver targeted solutions from day one.

“This is the moment women move beyond trial-and-error healthcare into precision longevity medicine.”

Mental health

Scaling startups risk increasing gender gaps, study finds

Published

on

Rapidly scaling startups often make rushed hiring choices that disadvantage women, a recent study has found.

The findings draw on more than 31,000 new ventures founded in Sweden between 2004 and 2018.

Researchers at the Stockholm School of Economics report that in male-led startups, scaling reduces the odds of hiring a woman by about 18 per cent, and the odds of appointing a woman to a managerial post by 22 per cent.

Mohamed Genedy is co-author and postdoctoral fellow at the House of Innovation, Stockholm School of Economics.

Genedy  said: “During those moments of rapid growth, even well-intentioned leaders can fall back on familiar stereotypes when assessing who they believe is best suited for the role.”

The patterns emerge even in Sweden, regarded as a highly gender-equal national context.

Founders with human resources-related education counteract these challenges.

In ventures led by founders with HR training, the odds of hiring a woman increase by more than 30 per cent, and the odds of appointing a woman to a managerial role increase by 14 per cent for the same level of growth.

Genedy said: “When founders have experience with structured hiring practices, the gender gaps shrink, and in some cases even reverse.

“This shows that getting the basics of HR right early on really pays off.

“When things start moving fast, founders with HR knowledge are less likely to rely on biased instincts and more likely to hire from a broader talent pool.”

Prior experience in companies with established HR practices also helps, though to a lesser degree.

It raises the likelihood of hiring women as ventures scale, but does not significantly affect managerial appointments.

The study additionally shows these patterns are not driven by founder gender alone.

Even solo female-led ventures display similar tendencies when growing rapidly, though to a somewhat lesser degree.

In female-dominated industries, rapid growth increases the hiring of women for regular roles but still reduces the likelihood that women are appointed to managerial positions.

“When scaling accelerates, cognitive bias kicks in for everyone. Female founders are not immune to these patterns,” said Genedy.

Continue Reading

News

Midi Health closes US$100m Series D

Published

on

Midi Health has closed a US$100m Series D, lifting the menopause care provider to a valuation above US$1bn and achieving unicorn status.

The company, originally focused on virtual menopause care, says it will expand to what it calls lifelong care, adding cardiology, obesity management, autoimmune survivorship and longevity services.

Joanna Strober is co-founder and chief executive officer of Midi Health.

She said: “This is validation for the movement we’re leading.

“Women’s health has been treated like an afterthought for too long.”

Midi reports it now sees more than 25,000 patients per week and has insurance coverage reaching 45 million women nationwide.

To support scale, the firm is rolling out a proprietary artificial intelligence engine intended to slot into clinical workflows.

It analyses patient charts before virtual visits to help personalise care, automates triage and documentation, and reviews data on midlife women to refine protocols.

The company has also strengthened its leadership. Jason Wheeler, formerly in senior finance roles at Tesla and Google, has been appointed chief financial officer. He joins chief marketing officer Melissa Waters, previously at Meta and Lyft, and chief commercial officer Matt Cook.

Each year, about two million women in the US enter menopause.

Untreated symptoms are estimated to cost the economy US$25bn annually.

Continue Reading

Entrepreneur

Women’s telehealth company WISP acquires TBD Health

Published

on

Women’s telehealth company Wisp has acquired TBD Health, a sexual health platform, in its first acquisition and expansion beyond direct-to-consumer care.

The deal adds TBD Health’s diagnostics infrastructure and hospital partnerships to Wisp’s platform, which the company says serves 1.8 million patients across the US.

Wisp, which describes itself as the largest women’s telehealth company in the US, said the acquisition marks a move into enterprise and hybrid care models that combine consumer-first digital care with hospital systems, enterprises and public health programmes.

TBD Health operates a sexual health and diagnostics platform across all 50 states, combining routine STI and HIV testing, virtual clinical support, and partnerships that help remove cost barriers for patients.

The company has established relationships with Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct.

Monica Cepak, chief executive of Wisp, said: “This acquisition reflects where healthcare is going and where women have been left behind.

“TBD Health brings the infrastructure and partnerships that allow us to move into hybrid and enterprise care quickly, while staying true to Wisp’s patient-first approach.

“Together, we are making preventative care more accessible especially to women and integrating them into proven care models.”

The companies say gaps in access remain in sexual health and preventive care, particularly for women.

While women account for 19 per cent of new HIV diagnoses in the US, they remain underserved by existing prevention models, which have historically been designed and marketed for men.

Of the 2.4 million people eligible for PrEP, a medicine that reduces the risk of getting HIV, only around 25 per cent are currently enrolled.

Daphne Chen, co-founder of TBD Health, said: “By joining forces with Wisp, we can provide partners with a turnkey solution for PrEP along with sexual health diagnostics and care that integrates seamlessly into their existing workflows, ensuring no patient falls through the cracks.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.